linjc16/ctgov huggingface dataset:
Application of Two Different Synthetic Sequential Media for the Human IVF-Embryo Transfer (IVF-ET) Program

Study Overview
=================
Brief Summary
-----------------
Quality-controlled commercial media have been used in many in-vitro fertilization (IVF) laboratories. However, commercial media are costly and difficult to compare directly because their exact compositions are not clearly indicated. Although commercially available media have commonly been used in most IVF programs worldwide, there are several advantages to the use of in-house synthetic sequential media at IVF laboratories. First, the results of quality control should be reliable due to a stringent protocol setting-up. Second, any direct supplementations or deletions of specific components are feasible to obtain good quality embryos and high pregnancy rates since those components can be defined. Finally, dependence on commercially available media diminishes so that the laboratory can more easily accommodate unexpected situations or problems, such as a sudden increase in IVF patients. Therefore, the present study was conducted to compare the efficacy of in-house MRC media in the human IVF-embryo transfer (ET) program to that of commercially available media.

Official Title
-----------------
Application of Two Different Synthetic Sequential Media for the Human IVF-ET Program

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Other: MRC media
* Other: Sydney IVF media


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing IVF treatment in our clinic during study period Exclusion Criteria: Females older than 40 years Patients showed fertilization failure Patients with less than two 2PN embryos

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MRC media<br>Use MRC media in the human IVF-ET program | Other: MRC media<br>* Culture media<br>|
| Active Comparator: Sydney IVF media<br>Use Sydney IVF media in the human IVF-ET program | Other: Sydney IVF media<br>* Culture media<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Embryo Quality |  | 3 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy and Implantation rates |  | 2 months |
Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).

Official Title
-----------------
Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.

Conditions
-----------------
Hypertension, Pulmonary

Intervention / Treatment
-----------------
* Drug: propofol and isoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study. Exclusion Criteria: Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia. |  | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP). |  | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propofol, isoflurane, pulmonary hypertension, congenital heart disease
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to identify and characterize novel non-coding and splicing variants that may contribute to genetic disorders. We will particularly focus on patients with a diagnosed genetic disorder that has inconclusive genetic findings.

Detailed Description
-----------------
To perform this study, we will use patient DNA and RNA that is isolated from blood samples. DNA will be sequenced (targeted capture and/or whole genome DNA sequencing (WGS)) to identify any non-coding single nucleotide variants (SNVs), smaller insertions/deletions (indels), or larger structural variants (SVs). RNA will be sequenced (RNA-seq) to identify genes that are expressed in a differential and/or allele-specific manner, which may indicate a functional non-coding or splicing variant. We will test the function of non-coding variants using high-throughput reporter assays and CRISPR based methodologies.

Official Title
-----------------
Identification and Characterization of Novel Coding, Splicing and Non-Coding Variants That Contribute to Genetic Disorders

Conditions
-----------------
Genetic Disease, Inborn Errors of Metabolism, Glycogen Storage Disease, Lysosomal Storage Diseases, Storage Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Subjects will have one or more of the following: Patients (probands) diagnosed with a genetic disease Patients (probands) with inconclusive genetic results Patients (probands) that have identical coding and/or splicing variants, but display highly diverse phenotypes Unaffected family members of probands Exclusion Criteria: There are no exclusion criteria for this study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of missing pathogenic protein coding variants |  | 2 years |
Role of Oral Glutathione in Skin Whitening

Study Overview
=================
Brief Summary
-----------------
Oral and intravenous glutathione have been used widely to whiten the skin. The investigators tested this hypothesis by giving oral glutathione for 4 weeks to medical students.

Official Title
-----------------
Glutathione as an Oral Whitening Agent: a Randomized, Double-blind, Placebo-controlled Study

Conditions
-----------------
Skin Whitening

Intervention / Treatment
-----------------
* Drug: glutathione
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy medical students Exclusion Criteria: history of skin cancer, especially melanoma consumption of any preparations containing glutathione within 1 month of enrollment pigmentary disorders or any dermatoses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: oral glutathione<br>glutathione, 500 mg, taken orally twice daily | Drug: glutathione<br>* 250 mg capsules, twice daily, orally<br>|
| Placebo Comparator: placebo capsules<br>identical-appearing placebo capsules | Drug: placebo<br>* 250 mg capsules, twice daily, orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin melanin index |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glutathione, melanin, whitening, UV spots, skin pigment
Atrial Fibrillation Detection Using Garmin Wearable Technology

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the feasibility of detecting atrial fibrillation (AF) in patients with AF using a wearable wrist device/smart watch.

Detailed Description
-----------------
Even though AF is common and associated with increased risk of stroke, quite often it goes undetected until late in the course of the condition. If AF can be detected with simpler tools like a smart watch, it would enable providers to identify patients with AF much earlier in the course of the condition (even before being seen by a physician) and hopefully be able to prevent stroke. This study is being done to identify a technology that can likely identify AF using a smart watch.

Official Title
-----------------
Atrial Fibrillation Detection Using Garmin Wearable Technology

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: Garmin Smart Watch
* Device: Garmin Chest Band


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with AF scheduled to undergo electrical cardioversion at the University of Kansas Health System Exclusion Criteria: Patients with no detectable PPG Hemodynamically unstable patients Patients who cannot give informed consent Patients with tattoos on the wrists

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AF Detection<br>Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure. | Device: Garmin Smart Watch<br>* Garmin Smart Watch<br>Device: Garmin Chest Band<br>* Garmin Chest Band<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of Garmin wearable device in detecting AF | PPG samples collected from Garmin wearable will be evaluated and calculated by Garmin custom | Visit 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smart Watch, Garmin, Wearable, Cardioversion
Hyaluronic Matrix Efficacy for Maxillary Sinus Augmentation

Study Overview
=================
Brief Summary
-----------------
Sinus augmentation is a predictable method when alveolar bone height is not sufficient for dental implant placement in posterior maxillary alveolar region..The aim of this prospective, randomized, controlled clinical study is comparison of hyaluronic acid originated matrix and equine derived xenograft with only xenograft use in sinus augmentation by micro computed tomography and histomorphometry.

Official Title
-----------------
Evaluation of Hyaluronic Matrix, Used With Xenograft, Efficacy in Sinus Augmentation by Histomorphometry and Micro Computed Tomography

Conditions
-----------------
Sinus; Dental

Intervention / Treatment
-----------------
* Procedure: Maxillary Sinus Augmentation
* Procedure: Maxillary Sinus Augmentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systemically healthy patients Requiring bilateral maxillary sinus augmentation (residual crest height ≤ 4 mm) Exclusion Criteria: Advanced systemic diseases Chronic medication use Maxillary sinus disease Current pregnancy Lactation Smoking habit

Ages Eligible for Study
-----------------
Minimum Age: 33 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Hyalossᵀᴹ matrix<br>Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation | Procedure: Maxillary Sinus Augmentation<br>* Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution<br>* Other names: Hyaloss matrix;Procedure: Maxillary Sinus Augmentation<br>* Control group sinuses filled with heterolog bone graft alone<br>|
| Active Comparator: Apatos alone xenograft<br>Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation | Procedure: Maxillary Sinus Augmentation<br>* Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution<br>* Other names: Hyaloss matrix;Procedure: Maxillary Sinus Augmentation<br>* Control group sinuses filled with heterolog bone graft alone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of newly formed bone calculated from bone biopsises by Micro-CT and Histomorphometry | Biological parameter obtained by analyzing bone biopsises | 4 months after surgery |
Maternal Physical Activity and Pregnancy Outcome

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the impact of maternal physical activity during pregnancy on pregnancy outcome. Primary, fetal growth during pregnancy abd birth weight will be examined.

Detailed Description
-----------------
During this study, the information on maternal physical activity will be collected and the impact on delivery and pregnancy complications as well as on neonatal complications will be evaluated. From the first visit at maternal care center, the information on socioeconomical and maternal characteristics will be collected. During pregnancy, fetal growth will be estimated by ultrasound. Physical activity will be measured using free app for measuring steps that mothers make during pregnancy. Using logistic regression, the impact of physical activity on pregnancy outcomes will be evaluated.

Official Title
-----------------
Maternal Physical Activity and Pregnancy Outcome

Conditions
-----------------
Pregnancy Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women with singleton pregnancies - Exclusion Criteria: Twins pregnancies. Mothers with preexisting conditions. Malformations.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal growth | Large for gestational age (LGA) small for gestational age (SGA) | birth weight at birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy complications | preeclampsia, diabetes, weight gain. | during pregnancy ( 9 months from start) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, physical activity, fetal growth
Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection

Study Overview
=================
Brief Summary
-----------------
Primary suture repair increases the risk for recurrence, the fact of benefit of mesh repair in elective situations is documented, and many studies have reported beneficial outcomes of mesh hernioplasty in emergency situations. Still there is controversy of using such grafts in presence of intestinal resection.

Detailed Description
-----------------
Patients with acutely incarcerated hernias (with small intestine contents) who underwent polypropylene mesh hernioplasty were included in this prospective study from June 2005 through Jan. 2011, patients were categorized into 2 groups who required intestinal resection anastomosis (group I)or not (group II).

Official Title
-----------------
Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection

Conditions
-----------------
Strangulated Hernia

Intervention / Treatment
-----------------
* Other: SURGERY
* Other: mesh repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: strangulated hernias Exclusion Criteria: above 75, under 18 recurrent hernia peritonitis pure omentum contents ASA above 3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: mesh repair<br>MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION | Other: SURGERY<br>* REPAIR OF STRANGULATED HERNIA with intestinal resection<br>* Other names: mesh hernioplasty;|
| Active Comparator: mesh repair without intestinal resection<br>mesh repair of strangulated hernia without resection | Other: mesh repair<br>* mesh repair of strangulated hernia without resection<br>* Other names: mesh hernioplasty without resection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| wound infection |  | 5 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operative time | the time from skin incision up to skin closure | 3hours | 
| morbidity | the perioperative complications | 5 months | 
| recurrence of the hernia | Recurrence of the hernia was defined as an apparent swelling or a palpable defect at the previous surgery site detected clinically or radiologically by ultrasound if needed | 6months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infection, Prosthesis, Recurrence, Strangulation
Foot Posture in People With Paralysis on One Side After Stroke

Study Overview
=================
Brief Summary
-----------------
People who have had a stroke often have difficulty walking and problems with their balance. The purpose of this project is to examine problems with foot postures in people who have weakness on one side of their body

Detailed Description
-----------------
The specific aims of this study are to: Describe foot posture in individuals with hemiplegia following stroke using a quantitative navicular drop test. Determine differences in people with normal, hypotonic, and hypertonic foot posture with regard to ankle range of motion, ankle strength, gait, and balance. This is an observational design study to describe relationships between the variables. Measurements will include both descriptive and quantitative measures. Thirty subjects with stroke will participate in one session of testing which will include: clinical assessment of foot posture using a descriptive classification system, quantitative measurement of navicular drop during standing, measurements of ankle range of motion, ankle strength, gait (lower extremity biomechanics and forceplate analysis), and static and dynamic balance. A chi-square test will be used to determine goodness of fit between classification with the descriptive system and the quantitative measurement. Independent one-way ANOVAs will be used to determine the mean differences in the foot posture groups for each of the dependent variables.

Official Title
-----------------
Foot Posture in People With Hemiplegia After Stroke

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects must have a diagnosis of a single stroke with resultant hemiplegia and be able to stand up from a seated position and walk 30 feet without assistance. Exclusion Criteria: Subjects will be excluded if they present with significant foot or ankle pathology, other medical problem that would affect gait or balance, or language / cognitive deficits that would impair ability to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |